Q8N6T7 (SIR6_HUMAN) Homo sapiens (Human)

NAD-dependent protein deacylase sirtuin-6 UniProtKBInterProSTRINGInteractive Modelling

355 aa; Sequence (Fasta) ; (Isoform 2)

Available Structures

42 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
Human SIRT6 in complex with allosteric activator MDL-801 Heteromer
P68431;
3-299
AR6;8L9;ZN;GOL;SO4;PEG;HDR;
Assess
The novel de-long chain fatty acid function of human sirt6 Heteromer
P68431;
3-296
ZN;APR;GOL;
Assess
SIRT6 bound to an H3K9Ac nucleosome Heteromer
P02281; P06897; P62799; P84233;
2-290
ZSL;ZN;
Assess
Structure of nucleosome-bound Sirtuin 6 deacetylase Heteromer
P04908; P06899; P62799; P84233;
14-293
Assess
Nucleosome Bound human SIRT6 (Composite) Heteromer
P02281; P06897; P62799; P84233;
26-285
ZN;
Assess
Human SIRT6 in complex with inhibitor 7702homo-6-mer13-298
PG4;O5L;AR6;ZN; 15×SO4;
Assess
Improved complex structure of human Sirtuin 6 with its inhibitor cis-resveratrolhomo-2-mer13-298
AR6;ZN;STL;PG4;EDO;SO4;CL;PEG;PGE;
Assess
Human Sirt6 in complex with the inhibitor S6020 and ADP-ribosehomo-2-mer13-298
AR6;ZN;EDO;PEG;SO4;V7R;CL;
Assess
Human Sirt6 in complex with ADP-ribose and the inhibitor catechin gallatehomo-2-mer13-298
AR6;ZN;EDO;SO4;XEG;
Assess
Human Sirt6 13-308 in complex with ADP-ribose and the activator fluvastatinhomo-2-mer13-298
AR6;ZN;GOL;SO4;115;
Assess
Human SIRT6 in complex with allosteric activator MDL-801 (3.2A)monomer4-299
AR6;ZN;8L9;GOL;SO4;PEG;G4X;
Assess
Human Sirt6 3-318 in complex with ADP-ribosemonomer4-298
AR6;ZN;NCA;GOL;SO4;
Assess
Crystal structure of human SIRT6monomer6-299
AR6;ZN;SO4;EDO;G4U;PEG;
Assess
Sirt6 apo structuremonomer7-299
AR6;ZN;TBU;GOL;
Assess
Human Sirt6 in complex with ADP-ribose and fragment 4-hydroxybenzamidemonomer13-298
AR6;ZN;PEG;P6G;SO4;HBD;CL;
Assess
Human Sirt6 in complex with ADP-ribose and fragment 1-methyl-L-histidinemonomer13-298
AR6;ZN;HIC;PEG;SO4;
Assess
Human Sirt6 in complex with ADP-ribose and fragment cis-resveratrolmonomer13-298
AR6;ZN;STL;PEG;SO4;PGE;CL;
Assess
Human Sirt6 in complex with ADP-ribose and fragment 6-O-methylguaninemonomer13-298
AR6;ZN;6GO;EDO;PG4;PEG;SO4;CL;
Assess
Human Sirt6 in complex with the inhibitor S6023 and ADP-ribosemonomer13-298
AR6;ZN;QTI;SO4;CL;
Assess
Human Sirt6 in complex with ADP-ribose and fragment nicotinamidemonomer13-298
AR6;ZN;NCA;EDO;PEG;SO4;
Assess
Human Sirt6 in complex with ADP-ribose and fragment 4-amino-6-chlorobenzene-1,3-disulfonamidemonomer13-298
AR6;ZN;PG4;EDO;PEG;SO4;I7B;CL;
Assess
Human Sirt6 in complex with ADP-ribose and fragment 3-(acetylamino)thiophene-2-carboxylic acidmonomer13-298
AR6;ZN;PEG;SO4;GV9;CL;
Assess
Human Sirt6 in complex with ADP-ribose and the activator quercetinmonomer13-298
AR6;ZN;SO4;QUE;EDO;PG4;
Assess
Human Sirt6 in complex with activator UBCS039monomer13-298
AR6;ZN;SO4;EDO;PGE;7M2;
Assess
Human Sirt6 in complex with ADP-ribose and the activator isoquercetinmonomer13-298
AR6;ZN;SO4;HW2;EDO;
Assess
Human Sirt6 in complex with ADP-ribose and fragment Isatinmonomer13-298
AR6;ZN;EDO;PG4;SO4;ISN;CL;
Assess
Human Sirt6 13-308 in complex with ADP-ribose and the activator MDL-801monomer13-298
AR6;ZN;8L9;SO4;
Assess
Human Sirt6 in complex with ADP-ribose and fragment 3-aminobenzamidemonomer13-298
AR6;ZN;PEG;SO4;3AB;CL;
Assess
Human Sirt6 in complex with activator UBCS58monomer13-298
AR6;ZN;SO4;EDO;PG4;7M5;
Assess
Human Sirt6 in complex with ADP-ribose and fragment sulfamethoxazolemonomer13-298
AR6;ZN;08D;PEG;EDO;SO4;
Assess
Human Sirt6 in complex with the inhibitor S6039 and ADP-ribosemonomer13-298
AR6;ZN;QY3;PEG;SO4;CL;
Assess
Human Sirt6 in complex with activator UBCS38monomer13-298
AR6;ZN;SO4;EDO;7N2;
Assess
Human Sirt6 in complex with small molecule UBCS40monomer13-298
AR6;ZN;SO4;7M9;
Assess
Human Sirt6 in complex with ADP-ribose and fragment pyroglutamic acidmonomer13-298
AR6;ZN;PCA;EDO;PGE;SO4;
Assess
Human Sirt6 in complex with ADP-ribose and fragment 4-nitrocatecholmonomer13-298
AR6;ZN;4NC;EDO;SO4;
Assess
Human Sirt6 13-308 in complex with ADP-ribosemonomer13-298
AR6;ZN;PGE;SO4;
Assess
Human Sirt6 in complex with ADP-ribose and the inhibitor trichostatin Amonomer13-297
AR6;ZN;PG4;EDO;SO4;TSN;
Assess
Human SIRT6 crystal structure in complex with ADP ribosemonomer13-297
UNX;ZN;AR6;SO4;
Assess
Human Sirt6 in complex with ADP-ribose and the activator cyanidinmonomer13-297
AR6;ZN;EDO;SO4;HWB;
Assess
Human Sirt6 3-318 in complex with ADP-ribose and the activator MDL-801monomer14-298
AR6;ZN;GOL;8L9;SO4;
Assess
Human SIRT6 crystal structure in complex with 2'-N-Acetyl ADP ribosemonomer13-296
A2N;ZN;SO4;UNX;
Assess
Crystal Structure of Human SIRT6monomer15-296
ZN;APR;SO4;UNX;
Assess

1 SWISS-MODEL model

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
7cl1.1.Amonomer0.894-299
THR;AR6;ZN;8L9;100.00
Assess

2 SWISS-MODEL models built on isoform sequence

TemplateIsoformOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 27cl1.1.Amonomer0.854-272
AR6;8L9;97.87
Assess
Isoform 26qcn.1.Amonomer0.5147-204
37.25
Assess